Efficacy and safety of abrocitinib in patients with moderate‐to‐severe atopic dermatitis with prior exposure to oral systemic immunosuppressants or biologic therapies: A post hoc analysis of the JADE clinical trials

• Egile Nagusiak: Melinda J. Gooderham (Egilea), Michael R. Ardern‐Jones (Egilea), Emma Guttman‐Yassky (Egilea), Mahreen Ameen (Egilea), Eric L. Simpson (Egilea), Gary Chan (Egilea), Pinaki Biswas (Egilea), Wing S. Chiu (Egilea), Melissa Watkins (Egilea)
• Formatua: Liburua
• Argitaratua: Wiley, 2023-12-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Abstract Background Patients with moderate‐to‐severe atopic dermatitis (AD) refractory to topical therapy might require treatment with systemic therapies, including biologics. Objectives To assess the efficacy and safety of abrocitinib monotherapy in patients who previously received systemic therapi...